SCIEX Launches the Next Generation of Data Independent Acquisition With Zeno SWATH DIA at ASMS 2022

Rhea-AI Summary

SciEX, part of Danaher Corporation (NYSE:DHR), has launched Zeno SWATH DIA, enhancing biomarker discovery through improved sensitivity and speed. The new system can quantify up to 2x the proteins in cell and plasma samples, significantly boosting clinical test development. Researchers can achieve large population-scale proteomic studies in weeks with 5-minute run-times, optimizing costs and sample usage. This advancement is expected to drive new therapies and precision medicine, reflecting a significant step forward in translational OMICS research.

Positive

• Zeno SWATH DIA quantifies up to 2x more proteins than previous methods, improving biomarker discovery.
• 5-minute run-times enable large-scale proteomic studies to be completed in weeks, enhancing research efficiency.
• Lower sample loads reduce costs, facilitating large population studies.

Negative

• None.

Enabling biomarker discovery and translation through increased sensitivity, throughput and robustness.

FRAMINGHAM, Mass.--(BUSINESS WIRE)-- SCIEX, a global leader in life science analytical technologies, and a company of Danaher Corporation (NYSE:DHR), launches Zeno SWATH DIA, a significant step forward in biomarker discovery and translation workflows.

Zeno SWATH DIA is the ultimate digital record of a sample that can enable researchers to discover more potential biomarkers to be used in the development of clinical tests and in the discovery of new therapies. By combining the sensitivity and robustness of the ZenoTOF 7600 system and the high dynamic range of Zeno SWATH DIA, researchers can now routinely quantify up x 2 the number of cell and plasma proteins than previously possible with SWATH approaches. The ability to quantify large numbers of lesser abundant proteins that were previously undetectable means that more potential biomarkers can be taken through to verification.

To enable translational research, this performance can be delivered at large scale. Run-times can be shortened to as little as 5 minutes with minimal compromise in proteome coverage. For the first time, large population-scale proteomic studies can be achieved in a matter of weeks, without compromising on the depth of information obtained. This means the potential for the development of clinical tests for early detection of disease is vastly increased.

“[With Zeno SWATH DIA] we can do things with higher sensitivity, faster,” said Markus Ralser, Director of the Institute of Biochemistry, Charité - Universitätsmedizin Berlin and group leader at The Francis Crick Institute, London. “If we can do things faster it means we can measure bigger sample sets. In clinical research this means that we can measure samples from more people at more timepoints.”

The sensitivity of Zeno SWATH DIA also enables large numbers of proteins to be quantified from sample loadings up to 10-fold lower than previous SWATH approaches. Lower sample loads mean reduced cost per sample in large scale studies, and minimized sample consumption from expensive in vivo models during drug development. Additionally, it creates opportunities for large population-scale sample collection methods such as patient-centric microsampling devices.

Markus Ralser added, “The higher sensitivity helps to reduce costs. In a 100,000 sample, project cost is very important. With Zeno SWATH DIA we can now do studies that we couldn’t do before due to cost alone.”

“To be able to quantify proteins at low abundance, over and over again, across large sample sets is the difference between a research curiosity and translational data with the potential to influence how patients are treated,” said Joe Fox, President at SCIEX. “The robustness of this approach is what will truly enable biomarker-centric approaches to medicine, driving a new era in translational OMICS research. Zeno SWATH DIA will enable the discovery of new biomarkers that allow for new therapies to be developed faster, and it has the potential to uncover the information to build precision medicine approaches.”

To learn more about Zeno SWATH DIA, see www.sciex.com/zenoswathdia.

About SCIEX

SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have been at the forefront of the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes.

Today, as part of the Danaher Corporation (NYSE:DHR) family of global science and technology companies, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers can quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.

That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.

For more information, visit sciex.com.

Let’s connect: Twitter, LinkedIn, Facebook, and Instagram.

Advances in human wellness depend on the power of precise science.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2022 DH Tech. Dev. Pte. Ltd. RUO-MKT-12-14839-A.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005301/en/

Lulu VanZandt

Senior Manager, Brand, Public Relations and Social Media

lulu.vanzandt@sciex.com

M: +1 (508) 782-9484

Source: SCIEX

FAQ

What is Zeno SWATH DIA launched by Danaher Corporation?

Zeno SWATH DIA is a new system for biomarker discovery, enabling researchers to quantify more proteins with enhanced sensitivity and speed.

How does Zeno SWATH DIA impact clinical research?

It allows for faster analysis of larger sample sets, improving the development of clinical tests and therapies.

What are the expected benefits of Zeno SWATH DIA for researchers?

Researchers can conduct population-scale proteomic studies quickly and cost-effectively, facilitating new therapeutic discoveries.

What company is behind the launch of Zeno SWATH DIA?

The launch is by SCIEX, a company of Danaher Corporation (NYSE:DHR).